Recent advances in targetable therapeutics in metastatic non-squamous NSCLC

Pranshu Bansal; Diaa Osman; Gregory N. Gan; George R. Simon; Yanis Boumber

doi:10.3389/fonc.2016.00112

Recent advances in targetable therapeutics in metastatic non-squamous NSCLC

Pranshu Bansal, Diaa Osman, Gregory N. Gan, George R. Simon, Yanis Boumber^*

^*Corresponding author for this work

Research output: Contribution to journal › Short survey › peer-review

29 Scopus citations

Abstract

Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.

Original language	English (US)
Article number	112
Journal	Frontiers in Oncology
Volume	6
Issue number	MAY
DOIs	https://doi.org/10.3389/fonc.2016.00112
State	Published - 2016
Externally published	Yes

Keywords

ALK
BRAF
C-MET
EGFR
HER2
NSCLC
ROS1
VEGFR2

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2016.00112

Cite this

@article{930dec7115ab4a3583839fd11a0fcf17,

title = "Recent advances in targetable therapeutics in metastatic non-squamous NSCLC",

abstract = "Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.",

keywords = "ALK, BRAF, C-MET, EGFR, HER2, NSCLC, ROS1, VEGFR2",

author = "Pranshu Bansal and Diaa Osman and Gan, {Gregory N.} and Simon, {George R.} and Yanis Boumber",

note = "Publisher Copyright: {\textcopyright} 2016 Bansal, Osman, Gan, Simon and Boumber.",

year = "2016",

doi = "10.3389/fonc.2016.00112",

language = "English (US)",

volume = "6",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

number = "MAY",

}

TY - JOUR

T1 - Recent advances in targetable therapeutics in metastatic non-squamous NSCLC

AU - Bansal, Pranshu

AU - Osman, Diaa

AU - Gan, Gregory N.

AU - Simon, George R.

AU - Boumber, Yanis

PY - 2016

Y1 - 2016

N2 - Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.

AB - Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.

KW - ALK

KW - BRAF

KW - C-MET

KW - EGFR

KW - HER2

KW - NSCLC

KW - ROS1

KW - VEGFR2

UR - http://www.scopus.com/inward/record.url?scp=84973563188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973563188&partnerID=8YFLogxK

U2 - 10.3389/fonc.2016.00112

DO - 10.3389/fonc.2016.00112

M3 - Short survey

C2 - 27200298

AN - SCOPUS:84973563188

SN - 2234-943X

VL - 6

JO - Frontiers in Oncology

JF - Frontiers in Oncology

IS - MAY

M1 - 112

ER -

Recent advances in targetable therapeutics in metastatic non-squamous NSCLC

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this